{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-087265","form_type":"8-K","ticker":"NTRA","cik":"0001604821","company_name":"Natera, Inc.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.524122+00:00","generated_at":"2026-06-12T08:23:01.310800+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Natera Q2 revenue $261.4M (+31.9% YoY); net loss narrows; raises FY 2023 guidance","bullets":["Total revenue $261.4M, up 31.9% YoY; product revenue $258.3M (+32.7%).","Net loss $110.8M ($0.97/shr) vs loss $145.2M ($1.50/shr) YoY; operating loss $112.4M.","Tests processed 617,200 (+23.5% YoY); oncology tests 83,500 (+88.9% YoY).","Raised FY 2023 revenue guidance to $1.015B-$1.035B vs prior $995M-$1.015B.","Won litigation: $19.35M damages from ArcherDX/Invitae; CareDx damages reduced to $0."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-087265","json":"https://secwatch.observer/filing/0001104659-23-087265.json","markdown":"https://secwatch.observer/filing/0001104659-23-087265.md","text":"https://secwatch.observer/filing/0001104659-23-087265.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604821/000110465923087265/0001104659-23-087265-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604821/000110465923087265/tm2322356d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T08:23:01.310800+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"40e59c2491143d2f18bb80484b197762f1be056d","claim":"Natera, Inc. reported the second quarter ended June 30, 2023 results: revenue $261.4 million, net income $110.8 million, EPS ($0.97) per diluted share. Guidance raised.","evidence_excerpt":"in cell-free DNA testing , today reported financial results for the second quarter ended June 30, 2023. Recent Strategic and Financial Highlights ● Generated total revenues of $261.4 million in the second quarter of 2023, compared to $198.2 million in the second quarter of 2022, an increase of 31.9%. Product revenues grew 32.7% over the same period. ● Processed","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1604821/000110465923087265/0001104659-23-087265-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$261.4 million"},{"label":"Net income","value":"$110.8 million"},{"label":"EPS","value":"($0.97) per diluted share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}